Month: August 2022

– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency – – Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer – – Secured flexible debt facility for up to $70 million – – Cash, cash equivalents and investments as of quarter end, together with first tranche of debt facility, funds cash flow requirements into the second quarter of 2024 – BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today reported financial results for the second quarter ended June 30, 2022 and provided recent business highlights. “I am...

Highlighted by an 84% Growth in Amazon Sales Conference call will be held on August 15th at 11AM ET VANCOUVER, British Columbia, Aug. 15, 2022 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC (BABY) (BABYF) (0YL.F) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company, today reported second quarter 2022 financial results for the period ending June 30, 2022. The financial statements and MD&A are available on SEDAR under the Company’s profile. Second Quarter 2022 Financial HighlightsRevenues were $2.3M, a 44% increase versus $1.6M in 1Q22, driven by the expansion of the toddler products across all channels, and the introduction of the new Toddler Omega product. Sales on Amazon.com increased 84% sequentially versus 1Q22, an impressive acceleration from prior periods. Else...

GreenLight human health research labs GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company ProgressGreenLight raised $108.4 million in private placement led by S2G Ventures with strong participation from existing and new investors with cash expected to fund critical programs through the first half of 2023.GreenLight and Samsung Biologics completed their first commercial-scale engineering run for mRNA COVID-19 vaccine.Human health partnerships include NIH to support COVID-19 vaccine development against emerging variants and a platform licensing agreement with Serum Institute of India (SII) to develop a vaccine for shingles and up to two other targets.Key milestones expected across plant health pipeline in 2022: anticipated EPA approval and launch of global-first foliar-applied RNA...

Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected by the end of the third quarter of 2022 On track to initiate a proof-of-concept clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations in the second half of 2022 On track to submit an Investigational New Drug (IND) application for the inhaled delivery of ELX-02 in the fourth quarter of 2022 On track to submit IND application for ZKN-013 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) patients with nonsense mutations cells in the fourth quarter of 2022 Announces results of ZKN-013 Dose Response Study in APCMin Model that confirmed the results from prior study which concluded in March 2022 and expect to submit an IND application for Familial Adenomatous Polyposis...

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update. “In the second quarter, we presented promising trial results from TPST-1120, our novel PPARα antagonist, at the ASCO Annual Meeting. This was the first presentation of clinical data from a Tempest program: a significant milestone for the company that was enhanced by its selection for a podium presentation,” said Stephen R. Brady, chief executive officer of Tempest. “In addition to progress on our other programs, we closed a financing with support from both a new, top-tier investor and our founding...

CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19 disease, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. “The second quarter was highlighted by the completion of several additional components of our full Phase I and non-clinical programs, a Fast Track designation, and collaborative engagement with the FDA around our PBI-0451 clinical development program. As a result of those regulatory interactions, we are pleased to confirm we will be initiating a Phase 2 trial with over 60 sites in the U.S. in the coming weeks,” said Thomas G. Wiggans, Chief...

TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) — Base Carbon Inc. (NEO:BCBN) (“Base Carbon”, or the “Company”) is pleased to announce its second-quarter 2022 financials results. All financial references are denominated in US dollars, unless otherwise noted. During the second quarter of 2022, amongst other achievements, the Company announced the execution of a carbon reduction project involving the distribution of 850,000 cookstoves and 364,000 water purifiers in Vietnam. Base Carbon facilitated a contractual project offtake agreement for initial carbon credit production which is anticipated to result in a payback period of 2.75 years on aggregate capital deployed. The distribution of the devices in Vietnam is expected to be completed by mid 2023, ahead of schedule, with approximately 285,000 devices having been distributed to date. The...